

Serial No. 10/602,330

PROPOSED CLAIM AMENDMENTS**RECEIVED**
CENTRAL FAX CENTER**FEB 13 2008**

Claims 1-118 (Canceled)

Claim 119 (Currently amended): A method to treat or ameliorate an innate
5 immune suppression condition by increasing the numbers of neutrophils in
circulation in a human, wherein the innate immune suppression condition is
associated with an infection, radiation, aging, autologous bone marrow
transplantation or stem cell transplantation comprising administering to the
human an effective amount about 100 mg, 150 mg, 200 mg, 250 mg or 300 mg
10 per day of 3 β ,17 β -dihydroxyandrost-5-ene once daily for 4, 5, 6 or 7 consecutive
days by intramuscular, intradermal or subcutaneous administration whereby the
number or activity of neutrophils in circulation in the human is increased.

Claim 120 (Previously presented): The method of claim 119 wherein the
15 3 β ,17 β -dihydroxyandrost-5-ene is administered once daily for 5, 6 or 7
consecutive days.

Claim 121 (Currently amended): The method of claim 120 wherein about
20 ~~50 mg, 75 mg,~~ 100 mg, 150 mg, 200 mg, 250 mg or 300 mg per day of 3 β ,17 β -
dihydroxyandrost-5-ene is administered.

Claim 122 (Previously presented): The method of claim 119 wherein the
25 3 β ,17 β -dihydroxyandrost-5-ene is administered once daily for 5 consecutive
days.

Claim 123 (Previously presented): The method of claim 122 wherein about
200 mg per day of 3 β ,17 β -dihydroxyandrost-5-ene is administered.

Claim 124 (Previously presented): The method of claim 123 wherein the
30 innate immune suppression condition is associated with radiation.

Serial No. 10/602,330

Docket No. 202 2D2

Claim 125 (Previously presented): The method of claim 124 wherein the 3 β ,17 β -dihydroxyandrost-5-ene is administered by intramuscular administration.

Claim 126 (Previously presented): The method of claim 122 wherein about
5 150 mg per day of 3 β ,17 β -dihydroxyandrost-5-ene is administered.

Claim 127 (Previously presented): The method of claim 122 wherein about 250 mg per day of 3 β ,17 β -dihydroxyandrost-5-ene is administered.

10 Claim 128 (Previously presented): The method of claim 122 wherein about 300 mg per day of 3 β ,17 β -dihydroxyandrost-5-ene is administered.

Claim 129 (Canceled): ~~The method of claim 120 wherein about 1.5 mg/kg/day, about 2 mg/kg/day, about 2.5 mg/kg/day, about 3.0 mg/kg/day, about~~
15 ~~4 mg/kg/day or about 6 mg/kg/day of 3 β ,17 β -dihydroxyandrost-5-ene is administered.~~

Claim 130 (Currently amended): The method of claim 119 wherein the innate immune suppression condition is associated with an infection ~~aging,~~
20 ~~autologous bone marrow transplantation~~ or stem cell transplantation.

Claim 131 (Currently amended): The method of claim 130 wherein the 3 β ,17 β -dihydroxyandrost-5-ene is administered once daily for ~~4, 5, 6 or 7~~
consecutive days 5 consecutive days.

25 Claim 132 (Currently amended): The method of claim 131 wherein ~~50 mg,~~
~~75 mg,~~ 100 mg, 150 mg, 200 mg, 250 mg or 300 mg per day of 3 β ,17 β -dihydroxyandrost-5-ene is administered.

Serial No. 10/602,330

Claim 133 (Previously presented): The method of claim 132 wherein the $3\beta,17\beta$ -dihydroxyandrost-5-ene is administered once daily for 5 consecutive days.

5 Claim 134 (Previously presented): The method of claim 133 wherein about 150 mg per day of $3\beta,17\beta$ -dihydroxyandrost-5-ene is administered.

Claim 135 (Previously presented): The method of claim 133 wherein about 200 mg per day of $3\beta,17\beta$ -dihydroxyandrost-5-ene is administered.

10 Claim 136 (Previously presented): The method of claim 133 wherein about 250 mg per day of $3\beta,17\beta$ -dihydroxyandrost-5-ene is administered.

Claim 137 (Previously presented): The method of claim 133 wherein about 300 mg per day of $3\beta,17\beta$ -dihydroxyandrost-5-ene is administered.

15 Claim 138 (Previously presented): The method of claim 135 wherein the $3\beta,17\beta$ -dihydroxyandrost-5-ene is administered by intramuscular administration.

20 Claim 139 (Canceled): ~~A method to treat or ameliorate an innate immune suppression condition associated with radiation, aging, autologous bone marrow transplantation or stem cell transplantation in a non-human primate comprising administering to the non-human primate an effective amount of $3\beta,17\beta$ -dihydroxyandrost-5-ene by intramuscular, intradermal or subcutaneous injection;~~
25 ~~whereby the number or activity of neutrophils in circulation in the non-human primate is increased.~~

Claims 140 (Canceled): ~~The method of claim 139 wherein the non-human primate is a cynomolgus monkey or a macaque monkey.~~

30

Claims 141-146 (Canceled)